Search results
We Are Transforming the Standard of Care and Pioneering New Markets. As the leader in RNA-targeted therapeutics for more than three decades, Ionis has focused every moment on advancing drug discovery, development, and providing hope for patients.
As a postdoctoral researcher or clinical fellow, you’ll work with world-class scientists and our academic collaborators to discover and/or develop new RNA-targeted therapeutics. Fellowship opportunities. Ionis is where passionate, driven people come together to help patients in need.
Ionis: A force for life. We are guided by world-class scientists and business leaders whose drive and passion to innovate is matched only by their commitment to deliver first-in-class and best-in-class medicines to the patients who need them. View 2023 Corporate Responsibility Report ».
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics.
May 7, 2019 · IONIS-MAPT Rx, also known as BIIB080, is an investigational antisense medicine designed to selectively inhibit production of the microtubule-associated protein tau (MAPT), or tau protein in the brain.
Our antisense therapies are designed to interact precisely with RNA, allowing us to create treatments that disrupt the disease process and change its course. With five marketed medicines and 10+ in mid- or late-stage development, our therapeutic breakthroughs are poised to continue to transform the futures of patients for years to come.
May 16, 2024 · Ionis plans to move ION582 into pivotal trial. Detailed ION582 data to be presented at upcoming medical meeting. CARLSBAD, Calif., May 16, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline data from the HALOS Phase 1/2a open-label study of ION582 in Angelman syndrome.
Ionis is guided by world-class scientists and business leaders whose passion to innovate is matched only by their commitment to deliver transformational medicines to patients who need them.
Dec 21, 2023 · As part of a global development and commercialization agreement, AstraZeneca and Ionis will commercialize WAINUA for the treatment of ATTRv-PN in the U.S. and are seeking regulatory approval in Europe and other parts of the world.
May 15, 2024 · Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases
